we are an early-stage bioscience company that focuses on research, development and commercialization of tcm for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder (“adhd”), autism spectrum disorder (“asd”) in infectious diseases such as covid-19. our goal is to improve the lives of adhd, asd and covid patients, their families and caregivers and become a market leader for the best tcm treatment globally.
Company profile
Ticker
RGC
Exchange
Website
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
RGC stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
2 Jan 24
6-K
Form of Letter of Lock-up Undertaking
15 Dec 23
20-F
2023 FY
Annual report (foreign)
27 Oct 23
6-K
Regencell Bioscience Holdings Limited Announces First Half 2023 Management Financial Results
15 Jun 23
6-K
SECOND EXTENSION OF letter of Lock-Up Undertaking
5 Jun 23
6-K
Report of Foreign Private Issuer
17 Mar 23
6-K
Report of Foreign Private Issuer
28 Feb 23
6-K
Report of Foreign Private Issuer
4 Jan 23
6-K
Report of Foreign Private Issuer
22 Dec 22
20-F
2022 FY
Annual report (foreign)
31 Oct 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
88.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 355.93 mm |
Total shares | 11.55 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Regencell (BVI) | 10.56 mm | $333.85 mm |
Digital Mobile Venture | 988.90 k | $10.38 mm |
MS Morgan Stanley | 301.00 | $6.53 mm |
BLK Blackrock | 238.00 | $5.17 mm |
Proequities | 0.00 | $0.00 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
29 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
22 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
13 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
11 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
6 Mar 24